Management methods for alleviating the side effects of larotinib/larlotinib-induced fatigue

Larotrectinib has shown good efficacy and tolerability in targeted therapy for NTRK fusion-positive tumors, but mild to moderate adverse reactions may still occur in some patients, and fatigue is one of the most common. This kind of fatigue is usually persistent and non-specific, and may be related to the effect of drugs on the central nervous system or the regulation of immune responses, which affects the patient's quality of life. Therefore, scientific management and relief of fatigue is particularly important.

First, patients should understand before treatment that fatigue may persist as a chronic side effect and proactively report fatigue symptoms to their doctor at the earliest stages. Doctors usually evaluate whether the dose or medication time needs to be adjusted based on the degree of fatigue. For example, appropriately delaying medication time and reducing daily activity schedules can help reduce the burden on the body. Mild to moderate fatigue generally does not require discontinuation of medication, while severe fatigue can be discontinued or the dosage reduced for a short period of time under the guidance of a doctor.

Secondly, maintaining a good daily routine and dietary management are also important means to relieve fatigue. Patients are advised to maintain regular sleep, exercise moderately, and avoid long-term bed rest to prevent physical decline. In terms of nutrition, we should pay attention to a high-protein, vitamin-rich diet and avoid excessive intake of high sugar and high fat. At the same time, blood routine and liver function need to be monitored to rule out other pathological fatigue factors such as anemia or liver toxicity caused by drugs.

Psychological factors cannot be ignored. Anxiety or depression during treatment may aggravate fatigue. Therefore, patients should be encouraged to participate in psychological counseling or mutual patient support activities to improve their emotional management capabilities. Some patients can also use auxiliary drugs, such as low-dose psychotropic drugs or central stimulants, for a short period of time under the evaluation of a doctor, but this must be done under professional guidance.

Reference materials:https://www.vitrakvi.com/